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Levosimendan is a positive inotropewith vasodilating properties (inodilator) indicated for decompensated heart
failure (HF) patients with low cardiac output. Accumulated evidence supports several pleiotropic effects of
levosimendan beyond inotropy, the heart and decompensated HF. Those effects are not readily explained by car-
diac function enhancement and seem tobe related to additional properties of thedrug such as anti-inﬂammatory,
anti-oxidative and anti-apoptotic ones. Mechanistic and proof-of-concept studies are still required to clarify the
underlying mechanisms involved, while properly designed clinical trials are warranted to translate preclinical
or early-phase clinical data into more robust clinical evidence. The present position paper, derived by a panel
of 35 experts in the ﬁeld of cardiology, cardiac anesthesiology, intensive care medicine, cardiac physiology, and
cardiovascular pharmacology from 22 European countries, compiles the existing evidence on the pleiotropic
effects of levosimendan, identiﬁes potential novel areas of clinical application and deﬁnes the corresponding
gaps in evidence and the required research efforts to address those gaps.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords:
Levosimendan
Inotropes
Heart failure
Cardiogenic shock
Cardioprotection
Organ protection
1. Introduction
Levosimendan is a positive inotropic agentwith vasodilating proper-
ties, also termed inodilator [1,2]. It acts on one hand by increasing the
sensitivity of troponin C to calcium in myocardial cells, hence leading
to inotropy, and on the other by opening the mitochondrial adenosine
triphosphate (ATP)-sensitive potassium channels in smooth muscle
cells, thus resulting in vasodilatation (Fig. 1). At higher doses, the drug
also acts as a phosphodiesterase III inhibitor [1]. In addition, it also acti-
vates ATP-sensitive potassium channels in mitochondria, an effect that
seems to hold a key role in protecting myocardial and potentially
other cell types against ischemia/reperfusion injury and perhaps other
insults. Levosimendan is currently indicated as an inotrope for acutely
decompensated heart failure patients with low cardiac output.
There is an accumulated body of preclinical and clinical evidence
indicating that levosimendan may be beneﬁcial for organs besides the
heart and in conditions beyond acute heart failure. In addition to the ex-
pected improvement of peripheral organs by virtue of the enhancement
of cardiac function, those beneﬁcial effects seem to be related to addi-
tional or pleiotropic properties of the drug beyond inotropy. As a result,
favorable effects have been documented in cardiac and non-cardiac
conditions other than acute heart failure.
The scope of the present position paper is to compile the evidence on
the pleiotropic effects of levosimendan and its potential use besides the
established indication. More speciﬁcally, the paper assembles the
existing pieces of evidence on the pleiotropic effects of levosimendan,
identiﬁes potential novel areas of clinical application and deﬁnes the
corresponding gaps in evidence and thus the required research efforts
Fig. 1. Levosimendan's main mechanisms of action (modiﬁed from Papp Z et al. Int J Cardiol 2012;159:82-7).
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to address those gaps. It was derived by a panel of 35 experts in the ﬁeld
of cardiology, cardiac anesthesiology, intensive care medicine, cardiac
physiology, and cardiovascular pharmacology from 22 European coun-
tries (Austria, Belgium, Croatia, Czech Republic, Denmark, Finland,
France, Germany, Greece, Hungary, Israel, Italy, Poland, Portugal,
Russia, Slovenia, Spain, Sweden, the Netherland, Turkey, the United
Kingdom, and Ukraine) with an expertise on levosimendan, who
convened in Athens on February 26–27, 2016 for reviewing the existing
data on the pleiotropic effects of levosimendan on the heart and non-
cardiac organs.
2. Levosimendan beyond inotropy: pleiotropic effects on the
cardiovascular system
2.1. Relaxation and diastole
Levosimendan exerts its positive inotropic action by direct binding
to troponin C, enhancing its afﬁnity for calcium in a calcium-
dependent manner [3,4]. Thus, the gradual decline in intracellular
calcium concentration during the course of diastole decreases the drug's
calcium sensitizing effect, thereby preventing a postulated adverse in-
ﬂuence on myocardial relaxation.
In animal studies, levosimendan seemed to improve left ventric-
ular (LV) diastolic function by increasing the rate of relaxation and
thus reducing relaxation time and by improving diastolic ﬁlling. In-
deed, besides inotropy, levosimendan had a positive lusitropic effect
on myocyte strips from human failing hearts, as it reduced relaxation
time [5]. Pagel et al. showed that levosimendan had no deleterious
effect on myocardial relaxation in normal dogs while it improved di-
astolic function in dogs with heart failure [6]. In another study in
conscious dogs with experimental HF, the drug reduced the time
constant of isovolumic relaxation (Tau, i.e., the exponential decay
of LV pressure during isovolumic relaxation) and increased the
peak rate of mitral ﬂow (dV/dtmax). Those effects persisted in exer-
cise, during which the drug prevented the increase in mean left atrial
pressure and end-diastolic pressure [7]. Besides the mechanism of
calcium-dependent troponin C binding, the positive lusitropic effect
of levosimendan may also be mediated in part through cyclic adeno-
sine monophosphate (cAMP) or ATP-sensitive potassium channel
activation [8,9].
In the clinical setting, intracoronary infusion of levosimendan in
patients with dilated cardiomyopathy increased dP/dtmax and re-
duced Tau, as documented by a micromanometer-tipped catheter
placed in the left ventricle, over a range of different heart rates,
hence exerting both an inotropic and a lusitropic effect, respectively,
without however affecting the force-frequency or the relaxation-
frequency relationship [10]. In a small randomized study in patients
with advanced HF, levosimendan improved transmitral ﬂow pat-
terns and mitral annulus diastolic velocities in addition to reducing
neurohormonal activation and pro-inﬂammatory cytokines [11].
Levosimendan has also been shown to have a positive effect on diastolic
function in other settings including cardiac surgery [12,13] and post-
ischemic stunning [14]. However, the effects of the drug on diastolic
function may be difﬁcult to interpret, as diastolic function may also be
improved by the reduction in LV afterload and preload resulting from
its vasodilatory effect, while changes in left atrial pressure and the pos-
itive chronotropic effect of levosimendanmay further affect LV diastolic
indices.
2.2. Remodeling
Levosimendan has been shown to attenuate cardiac remodeling in
different animal experimental settings. In a model of hypertension–
induced myocardial hypertrophy in salt-sensitive Dahl/Rapp rats on a
high-salt diet, the active metabolite of the drug, OR-1896, prevented
hypertrophy when given orally for 7 weeks, without affecting blood
pressure [15,16]. In addition, the drug improved cardiac function, atten-
uated the increase in natriuretic peptides and reduced animalmortality.
The above beneﬁcial effects were associated with reduction in cardio-
myocyte apoptosis, attenuation ofmyocardial calcium-handling protein
disturbances (decrease in SERCA2, and SERCA2a/Na-Ca exchanger
ratio) and reduction in myocardial senescence, as determined by
cardiac p16 mRNA expression. In another model of post-infarct cardiac
remodeling in diabetic Goto-Kakizaki rats, oral levosimendan, given for
up to 12 weeks post myocardial infarction, reduced myocardial remod-
eling [17–19]. At the same time, the drug improved cardiac function, re-
duced heart failure, attenuated cardiomyocyte apoptosis, reduced levels
of myocardial IL-6, monocyte chemo-attractant protein-1 and connec-
tive tissue growth factor and myocardial senescence and prevented
disturbances in myocardial calcium-handling protein expression. In
addition, it also modulated (up- or down-regulated) the expression
of several genes, including those involved in the renin–angiotensin–
aldosterone system and in glycerol-lipid metabolism.
A favorable modulation of extracellular matrix metabolism by
levosimendanmay partly explain the prevention of cardiac remodeling.
More speciﬁcally, levosimendan prevented in vitro the migration of
adult rat cardiac ﬁbroblasts induced by IL-1β, a key process in cardiac
remodeling, by inhibiting the secretion of matrix metalloproteinase
(MMP)-9 [20]. In addition, in the clinical setting, levosimendan reduced
the circulating levels ofMMP-2 in patients with acutely decompensated
heart failure [21,22].
2.3. Endothelial function
In animal studies, levosimendan induced an increase in coronary
blood ﬂow in anesthetized pigs by enhancing nitric oxide (NO) produc-
tion [23]. This effectwasmediated by an increase in the expression of en-
dothelial NO synthase (eNOS) through activation of extracellular-signal-
regulated kinases (ERK), protein kinase B (Akt/PKB) and p38 mitogen-
activated protein kinases (MAPK), while activation of mitochondrial
ATP-sensitive potassium channel was also involved. In a small random-
ized clinical study in hospitalized HF patients levosimendan improved
endothelial function when compared to placebo in vivo, as documented
by an increase in endothelium-dependent ﬂow-mediated dilatation of
brachial artery. This effect was associated with a reduction in plasma
levels of soluble intercellular adhesion molecule-1 (sICAM-1) and
soluble vascular cell adhesion molecule-1 (sVCAM-1) [24].
2.4. Ventriculo-arterial coupling
Ventriculo-arterial coupling describes the relationship between
myocardial contractility and arterial afterload and thus represents a
measure of the efﬁciency of the cardiovascular system. Ventriculo-
arterial coupling is determined by the ratio of end-systolic elastance
(Ees, i.e., the slope of end-systolic pressure-volume relationship) to
effective arterial elastance (Ea, i.e., the ratio of end-systolic arterial pres-
sure to stroke volume). In anesthetized dogs, levosimendan increased
LV Ees/Ea ratio, which is consistent with an improvement in LV-
arterial coupling, as a result of an increase in LV contractility (and thus
in Ees) and a reduction in LV afterload (and thus in Ea) [25]. The same
effect was also observed in pulmonary circulation. In an experimental
model of acute right ventricular (RV) dysfunction in pigs, induced by re-
petitive episodes of RV ischemia/reperfusion in the presence of tempo-
rary pulmonary artery constriction, levosimendan restored RV-arterial
coupling to normal levels, as it increased RV contractility and reduced
RV afterload [26].
In the clinical setting, in patientswith ischemic LVdysfunction under-
going elective coronary artery bypass grafting surgery, levosimendan
administered after induction of anesthesia and before the operation,
both increased LV contractility and reduced LV afterload and thus
improved LV-arterial coupling [27].
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2.5. Ischemia-reperfusion, stunning and coronary circulation
Levosimendan may protect the myocardium against ischemia and
reperfusion injury. The drugs bears ischemic conditioning properties,
as it activates mitochondrial ATP sensitive potassium channels that
hold a key role in myocardial protection [28]. Animal studies in pigs,
rabbits and rats have shown that levosimendan administration before
index ischemia or during reperfusion limited infarct size, an effect
consistent with pre- and post-conditioning [29–32]. Besides infarct
size limitation, the drug also had a favorable effect on the incidence of
arrhythmias, myocardial functional recovery and myocardial metabo-
lism during reperfusion [30–33]. In addition to mitochondrial ATP-
sensitive potassium channel activation, modulation of NO synthesis
and involvement of the phosphatidylInositol 3-kinase (PI3K) pathway
also seem to play a role in pharmacologic conditioning afforded by
levosimendan [30,31]. The conditioning effects of the drug may have
implications for acute coronary syndromes undergoing reperfusion
and for elective cardiac surgery [29]. Indeed, in a small randomized
study in patients undergoing elective coronary artery bypass surgery,
pretreatment with levosimendan reduced post-operative troponin
elevation [34].
Levosimendan has also been shown to improve systolic and dia-
stolic function of stunned myocardium in the context of acute coro-
nary syndromes (ACS). More speciﬁcally, in ACS patients who
underwent coronary angioplasty, the drug caused an upward and
leftward shift of the pressure-volume loops, consistent with enhance-
ment of contractility [14]. In addition, levosimendan also improved
echocardiographic indices of LV diastolic function after primary angio-
plasty in a randomized study of patients with anterior myocardial
infarction [35].
Finally, besides the ischemic conditioning and anti-stunning effects,
levosimendan also increased coronary blood ﬂow in anesthetized
pigs by enhancing NO release, as stressed earlier [23]. The drug has
further been shown to attenuate vasospasm induced by norepinephrine
or 5-hydroxytryptamine in isolated grafts from internal mammary
and radial arteries, along with an anti-aggregation effect on platelets
in vitro [36,37], an effect that may also have implications in coronary
artery bypass grafting surgery.
2.6. Inﬂammation
Levosimendan has been shown to exert anti-inﬂammatory effects
in vitro. More speciﬁcally, the drug attenuated the expression of pro-
inﬂammatory cytokines interleukin (IL)-6 and IL-8 induced by IL-1β in
isolated human myocardial cells as well as the expression of adhesion
molecules E-selectin and ICAM-1 and the adhesion of polymorphonu-
clear neutrophils to isolated human endothelial cells [38]. Those
effects were partly mediated by the activation of mitochondrial ATP-
dependent potassium channels. In addition, the drug inhibited the pro-
duction of reactive oxygen species in isolatedhumanpolymorphonucle-
ar neutrophils [39].
Clinical studies have shown that levosimendan bears anti-
inﬂammatory effects in HF patients. In a series of small randomized
trials in patients hospitalized with acutely decompensated HF,
levosimendan reduced the plasma levels of high-sensitivity C-reactive
protein, IL-6, tumor necrosis factor (TNF)-alpha, TNF-alpha receptor
and soluble Fas and attenuated the increase of circulating markers of
oxidative and nitrosative stress (protein carbonyls, malondialdehyde
and nitrotyrosine) observed in the placebo group while improving car-
diac function and reducing natriuretic peptides [40–43]. Some of those
anti-inﬂammatory effects were sustained for up to 30 days after a single
24-hour infusion [43]. The anti-inﬂammatory effects of levosimendan,
besides reﬂecting the improvement in cardiac function and central he-
modynamics in the context of decompensated HF, are per se important
and may have further implications in other conditions besides HF, such
as sepsis and septic shock, as described in detail later.
3. Levosimendan beyond the heart: effects on peripheral organs
3.1. Kidneys
In preclinical studies in vivo, levosimendan has been shown to pro-
tect the kidneys from ischemia and reperfusion injury induced by
renal artery clamping in anesthetized pigs and in rabbits by preventing
oxidative stress and apoptosis [44,45]. These beneﬁcial effects were
shown to be dependent on mitochondrial ATP-sensitive potassium
channel opening and NO synthase activation [44]. The renal anti-
oxidative properties of levosimendan have also been documented in
male Wistar-albino rats [46]. Furthermore, the drug has been shown
to protect mice from experimental renal dysfunction caused by
endotoxemia [47]; levosimendan prevented lipopolysaccharide (LPS)-
induced acute renal failure, without abrogating LPS-induced inﬂamma-
tory response, an effect that resulted possibly from its vasoactive prop-
erties. In addition, the drug blocked angiotensin II-mediated mesangial
cell contraction in the context of endotoxemia, which in turn may
theoretically increase glomerular ﬁltration area and thus glomerular
ﬁltration rate (GFR) [47].
In clinical studies, levosimendan has been shown to protect renal
function after cardiac surgery as well as in the context of acute HF
[48]. In a small randomized study in 30 sedated and mechanically ven-
tilated patients having undergone uncomplicated cardiac surgery with
cardiopulmonary bypass and with normal renal function assessed by
renal vein thermodilution, levosimendan increased cardiac index,
renal bloodﬂowandGFR and reduced renal vascular resistance, without
affecting renal oxygen consumption or renal oxygen extraction com-
pared to placebo [49]. Therefore, the renal effects of levosimendan can
be attributable to the increase in cardiac output in combination with af-
ferent arteriole vasodilatation. In contrast, dopamine causes vasodilata-
tion both on the afferent and the efferent arteriole of the glomerulus,
thus increasing profoundly renal blood ﬂow without having a notable
effect on GFR. In a larger randomized trial in 128 patients with impaired
LV function who underwent mitral valve surgery, levosimendan, given
after the removal of the aortic clamp on top of standard inotropic ther-
apy, prevented renal function worsening during the ﬁrst postoperative
days compared to placebo [50]. In another small randomized trial
in 21 patients with acute HF and moderate renal impairment,
levosimendan improved central hemodynamics (cardiac index, pulmo-
nary capillary wedge pressure) and increased renal blood ﬂow as
evaluated by renal artery Doppler, increased GFR and urine output
compared to placebo over 3 days [51]. The drug also prevented renal
function worsening during the ﬁrst week after cardiac transplantation
compared to standard inotropic therapy in a randomized study in 94
patients [52]. The reno-protective effects of levosimendan have further
been conﬁrmed by threemeta-analyses, two concerning cardiac surgery
patients and one amixed population. Levosimendan reduced the risk of
acute kidney injury and the risk of dialysis and in one of the meta-
analyses also reduced mortality [53–55].
In acute HF, levosimendan has been shown to bemore effective than
dobutamine in improving GFR over a period of up to 72 h in a random-
ized study in 88 patients [56]. Particularly in patients with acute HF and
renal function impairment, a frequent comorbidity in those patients, a
24-hour levosimendan infusion but not placebo increased GFR for up
to 14 days after infusion, as shown by a randomized study in 66 patients
[57]. In an observational study in 96 patients with acute HF and im-
paired GFR, levosimendan reduced the incidence of in-hospital renal
function worsening and the levels of cystatin C [58]. The renoprotective
effect of levosimendan in the context of acute HF seems to be mediated
through an increase in renal bloodﬂowby renal artery vasodilatation, as
documented by intravascular renal artery Doppler [51]. Levosimendan
also improved renal function in advanced HF patients awaiting cardiac
transplantation, as shown by a randomized trial in 40 patients [59].
Three ongoing randomized trials in severe HF with impaired renal
function (ELDORADO, NCT02133105), in adult cardiac surgery patients
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(LEVOAKI, NCT02531724) and in pediatric cardiac surgery patients
(MiLe-1, NCT02232399), are expected to shed some new light on the
renal effects of levosimendan.
3.2. Liver
Levosimendanhas protective effects during hepatic ischemia and re-
perfusion injury as demonstrated both in vitro, in isolated rat hepato-
cytes, and in vivo [60–62]. More speciﬁcally, the drug protected the
hepatocytes from oxidative and apoptotic changes after ischemia-
reperfusion through mechanisms dependent upon the modulation of
NO release by eNOS and inducible NOS (iNOS), the activation of mito-
chondrial ATP-dependent potassium channels and the activation of cy-
clooxygenase (COX)-1 [60,61,63]. Such ﬁndings may have important
implications for liver surgery, particularly hepatic transplantation.
Experimental and clinical evidence suggests that levosimendan
may act as a selective hepatic vasodilator, as it was able to improve
hepatic perfusion through both the hepatic artery and the portal vein.
Levosimendan increased blood ﬂow and reduced vascular resistance
in liver as documented by the radioactive microsphere technique in
anesthetized dogs [64]. The drug also improved hepatic microcircula-
tion and portal blood ﬂow as measured by laser Doppler ﬂowmeter
and ultrasound ﬂowmeter probes in rats model of hepatic ischemia
[60,62]. Similar effects on portal circulationwere found in experimental
sepsis in pigs, where the vascular response to levosimendan was not
accompanied by any changes in systemic blood pressure [65].
Similarly, in patients with low cardiac output following cardiac surgery,
levosimendanboth increased portal vein blood ﬂowand reduced hepat-
ic artery resistance [66]. Finally, in septic shock patients, levosimendan
increased hepatic perfusion, as documented non-invasively by indocya-
nine green plasma disappearance rate (ICG-PDR) [67].
3.3. Gut and splanchnic vasculature
In addition to the beneﬁcial effects on hepatic blood ﬂow,
levosimendan has been shown to improve bloodﬂowand reduced vascu-
lar resistance in the small intestine in anesthetized dogs and increase gas-
tric mucosal oxygenation in anesthetized dogs [64,68]. The drug also
improved intestinal blood ﬂow and intestinalmucosal oxygenation in ex-
perimental sepsis both in pigs and in sheep [65,69], although this latter ef-
fect was questioned by another study in pigs with endotoxemic shock, in
which levosimendan did not increase hepatosplanchnic perfusion [70].
In the clinical setting, in patients undergoing abdominal aortic
surgery, levosimendan improved gastric mucosal oxygenation, as
documented by gastric mucosal-arterial pCO2 gradient, but it did not
increase total splanchnic blood ﬂow, as estimated by ICG-PDR [71].
3.4. Lungs and respiratory muscles
Levosimendan has further been shown to affect lungs and pulmo-
nary function. In animal studies, the drug protected the lungs in rats
against direct ischemia and reperfusion injury accomplished by unilat-
eral hilar occlusion but also against acute lung injury in the context of
sepsis, myocardial ischemia or limb ischemia [72–77]. Besides its well
known anti-ischemic, anti-apoptotic and anti-inﬂammatory properties
that seem to be effective also in lungs, thedrug further causes vasorelax-
ation in pulmonary circulation through activation of ATP-sensitive
potassium channels and activation of cAMP and cGMP pathways [78].
Since this effect concerns both pulmonary arteries and pulmonary
veins, levosimendan could be supposed to cause a reduction of both
RV afterload and pulmonary hydrostatic pressures. As a result, in a
pilot randomized clinical study, levosimendan improved RV function
through pulmonary vasodilatation in septic patients with acute respira-
tory distress syndrome (ARDS) [79].
Respiratory muscle weakness may develop in the course of several
conditions including heart failure, chronic obstructive pulmonary
disease (COPD) and in ventilated critically ill patients [80]. Among
other factors, reduced calcium sensitivity of contractile proteins plays
an important role in respiratory muscle dysfunction in these conditions
[80]. Levosimendan has been shown to enhance in vitro the contractility
of isolated diaphragm muscle ﬁbers from healthy subjects and COPD
patients as well as from rats with heart failure by improving calcium
sensitivity, acting mainly on slow ﬁbers and less on fast ﬁbers [81]. In
vivo, the drug attenuated oxidative tissue damage in diaphragm of me-
chanically ventilatedmicewith septic shock [82]. In a small randomized
placebo controlled trial, levosimendan has been shown to improve
contractile efﬁciency of the diaphragm in healthy subjects and reverse
the development of fatigue after inspiratory muscle loading [83].
3.5. Central nervous system
Levosimendan is known to cross the blood–brain barrier and may
act beneﬁcially in the central nervous system (CNS) by causing arterial
vasodilation and/or neuro-protection. Indeed, there is very limited
experimental and clinical evidence suggesting a potential neuro-
protective role of the drug against brain and spinal cord ischemia and
reperfusion injury, as well as against brain damage in the context of
subarachnoid hemorrhage (SAH).
Levosimendan has been shown to protect the brain in vitro from
mechanical trauma in isolated hippocampus slices from mice [84]. In
in vivo animal studies of CNS ischemia and reperfusion, levosimendan
increased blood ﬂow, limited brain infarct size and edema and attenuat-
ed local TNF-a and ICAM-1 expression in male Wistar rats subjected to
60-minmiddle cerebral artery occlusion, without affecting neurological
outcome or mortality [85]. In addition, it also protected spinal cord
from neurological, histopathological and biochemical changes in New
Zealand rabbits subjected to 30-min abdominal aorta clamping [86].
However, in another in vivo study, the drug had no effect on cerebral
perfusion or edema or local expression of pro-inﬂammatory cytokines
in male Wistar rats subjected to ischemia by 15-min carotid artery
clamping combined with hypoxia by ventilation with 6% oxygen [87].
In human studies, a 48-hour levosimendan infusion increased cerebral
intravascular oxygenation, as evaluated by near-infrared spectroscopy, in
16 critically ill infants suffering from low cardiac output syndrome due to
congenital cardiac defects, without a simultaneous change in cerebral
blood volume [88]. The amelioration of cerebral oxygenation in the ab-
sence of change in cerebral blood volume could be attributed to the de-
creased blood transit time due to the global circulatory improvement
rather than to cerebral vasodilation per se. In another small study, howev-
er, oral levosimendan, given in 5 escalating doses at 18-day intervals per
each dose, increased cerebral blood ﬂow in 16 patients with ischemic
stroke or transient ischemic attack, as documented by transcranial Dopp-
ler assessment of middle cerebral artery ﬂow velocities [89].
Subarachnoid hemorrhage may result in detrimental neurological
effects through sympathetic overstimulation, oxidative stress, inﬂam-
matory activation and myocardial stunning that may lead, in turn, to
decreased cerebral perfusion, cerebral vasospasm, dysfunction of
blood-brain barrier, edema and ﬁnally brain injury [90]. Levosimendan
may protect the brain from those effects by its vasodilatory, anti-
inﬂammatory and cardiac enhancing properties. Indeed, in an experi-
mental SAH model in rabbits, levosimendan prevented cerebral vaso-
spasm [91], while a case report in a patient with SAH documented
improved neurologic outcomes [92].
4. Levosimendan beyond acute heart failure: effects on other
cardiovascular and non-cardiovascular conditions
4.1. Advanced HF
Patients with advanced heart failure suffer from marked limitation
of exercise capacity, severe symptoms, often unresponsive to drug ther-
apy, lack of tolerance to disease-modifying therapies, progressive
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deterioration of multiple organ function and frequent hospital admis-
sions [93]. These patients are often dependent on continuous inotropic
support for severe symptoms. In this setting, repetitive or pulsed
levosimendan infusions, that take advantage of the long-lasting metab-
olite OR-1896, represent an attractive alternative. Several clinical stud-
ies have provided encouraging evidence on this approach in terms of
functional status, hemodynamics, neurohormonal and inﬂammatory
markers, quality of life and clinical outcomes [41,94–102]. A recently
publishedmeta-analysis of 7 randomized trials on 438 patients showed
a signiﬁcant reduction in mortality after an average follow-up of
8 months [odds ratio (OR) versus placebo, 0.54 (0.32–0.91), p = 0.02]
[103,104]. However, the recently published multicenter randomized
trial LevoRep failed to meet its primary endpoint of improvement in
functional capacity and quality of life, as assessed by 6-min walked
distance and Kansas City Cardiomyopathy Questionnaire, although it
documented a reduction in mortality, acute heart failure episodes and
heart transplantation [105]. The available evidence on the intermittent
use of levosimendan in advanced HF is reviewed in detail in an expert
consensus document [106].
4.2. Sepsis and septic shock
Levosimendan has been shown to improve multiple aspects of organ
dysfunction in animal models of sepsis. In long series of studies in
animals including rabbits, pigs, rats and sheep with experimental sepsis,
levosimendan improved cardiac systolic and diastolic function, central
haemodynamics, as well as liver, kidney and pulmonary function and en-
hanced hepatic and splanchnic perfusion, prevented pulmonary
vasoconstriction and acute lung injury [65,73,74,82,107–110]. In terms
of underlying mechanisms, levosimendan exerted anti-inﬂammatory ef-
fects both in vivo and in vitro and decreased iNOS expression and activity
and NF-kappaB-dependent transcription in vitro [107,109,111,112].
In the clinical setting, according to a meta-analysis of 7 studies on
246 patients with severe sepsis or septic shock, levosimendan signiﬁ-
cantly reduced mortality compared to standard inotropic therapy (risk
ratio, 0.79 (0.63–0.98), p = 0.03), while it was also followed by higher
cardiac index and lower lactate concentration, despite similar blood
pressure levels and norepinephrine use [113]. Additional studies have
provided more insights into the potential mechanisms underlying this
apparent beneﬁcial effect in septic patients. These studies have
documented improvement in cardiac performance, central hemody-
namics and peripheral organ perfusion, including renal, hepatic
and gastrointestinal perfusion, enhancement of renal and hepatic
function, improvement of right ventricular performance in ARDS,
resuscitation of microcirculation and enhancement of mitrochondial
function with anti-oxidative properties [48,67,79,114–116]. The ongo-
ing Levosimendan for the Prevention of Acute oRgan Dysfunction in
Sepsis (LeoPARDS) study will provide further evidence on the efﬁcacy
of levosimendan in improving organ dysfunction and the underlying
mechanisms in patients with septic shock and evaluate its biological
mechanisms of action [117].
4.3. Perioperative prophylaxis
The aforementioned protective effects of levosimendan against is-
chemia and reperfusion injury in multiple organs including the heart,
kidneys, liver, lungs, brain and spinal cord as well as its vasodilating
effects on several vascular beds such as the coronary, pulmonary
circulation and splanchnic circulation may render the drug useful for
the peri-operative protection of patients undergoing cardiac or non-
cardiac surgery. Indeed, several studies have provided encouraging
evidence on favorable effect of the drug when given peri-operative in
patients undergoing different types of cardiac surgery including
coronary artery bypass grafting, aortic valve replacement or correction
of congenital defects, particularly in patients with poor cardiac func-
tion [12,13,34,118–124]. The available evidence on the perioperative
use of levosimendan in cardiac surgery has recently been compiled
by a European expert panel [125]. The potential role of levosimendan
in optimizing cardiac performance in HF patients undergoing
major non-cardiac surgery has also been stressed [126]. Τhe ongoing
CHEETAH trial (NCT00994825) of levosimendan infusion in patients
who develop low cardiac output syndrome after cardiac surgery is
designed to enroll 1000 patients and is expected to provide impor-
tant insights into the management of patients undergoing cardiac
surgery.
4.4. Weaning
Given its potential beneﬁcial effects on respiratory function,
levosimendan may potentially facilitate weaning from mechanical
ventilation. In addition, it also seems to improve splanchnic mucosal
oxygenation that is depressed by mechanical ventilation [127],
while the effects of the drug on respiratory function in patients with dif-
ﬁcult weaning from mechanical ventilation are being investigated
(NCT01721434). It has further been suggested that levosimendan may
be used for theweaning of patients frommechanical circulatory support
or treatment with other inotropes or vasoconstrictors [128–130], while
it has been shown effective in facilitating weaning from cardiopulmo-
nary bypass in patientswith LVdysfunction after coronary artery bypass
surgery [131].
4.5. Subarachnoid hemorrhage
Subarachnoid hemorrhage, besides its detrimental neurologic
effects, may also cause myocardial stunning through sympathetic
over-activation that may it turn lead to stress cardiomyopathy or car-
diogenic shock [90]. Besides its potentially neuro-protective role,
levosimendan may also improve cardiac function in neurologically
stunned myocardium in the context of SAH, as suggested by reports of
4 cases in total treated with levosimendan for either cardiogenic shock
or stress cardiomyopathy associated with SAH [92,132,133].
5. Summary and call for action
Levosimendan is currently approved in many countries worldwide
for acutely decompensated heart failure with low cardiac output.
Based on the compiled evidence described in detail above, besides the
typical scenario of low cardiac output, the drug is expected to have
favorable effects in other conditions associatedwith acutely decompen-
sated heart failure, including acute coronary syndromes, RV failure, sub-
arachnoid hemorrhage and cardiac surgery, eitherwith preserved organ
function or complicated by renal dysfunction, hepatic injury or cardio-
genic shock with multi-organ dysfunction. The above clinical scenarios
are outlined in Fig. 2.
Bearing in mind the accumulated evidence, levosimendanmay have
favorable effects in several conditions beyond the heart and acute heart
failure. It can confer protection of renal, hepatic, brain and spinal cord
function in cases with ischemia and reperfusion injury. Moreover,
levosimendan can be effective during brain injury or cardiac stunning
caused by subarachnoid hemorrhage, respiratory dysfunction, sepsis
and septic shock, peri-operative events, advanced heart failure as well
as during weaning from mechanical ventilation, inotropes or mechani-
cal circulatory support (Fig. 3). All the aforementioned clinical condi-
tions outlined in Figs. 2 and 3 represent potential challenging ﬁelds of
clinical research. At least preclinical data are available for all of those
ﬁelds, while clinical evidence has also been accumulated for some of
them, thus providing the grounds for further clinical testing. In addition,
further research ﬁelds are emerging. Preclinical evaluation of the
cardioprotective effects of levosimendan against doxorubicin-induced
toxicity is in progress and the ﬁrst results are expected shortly [Personal
communication]. A call for action for further research on the effects of
levosimendan beyond inotropy, the heart and acute heart failure is
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framed in Table 1. Additional preclinical studies in ﬁelds with limited
evidence, early-phase proof-of-concept clinical trials in ﬁelds where
there is sufﬁcient preclinical evidence and more advanced-phase
clinical trials in ﬁelds with sufﬁcient early-phase clinical evidence con-
stitute the required next steps to advance our knowledge and explore
potential novel indications of levosimendan.
Fig. 2. Clinical scenarios in the context of acutely decompensated heart failure, in which levosimendan may play a beneﬁcial role.
Fig. 3. Summary of the favorable effects of levosimendan beyond inotropy, the heart and acute heart failure.
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